BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia
and Phase Ib).
The Phase Ia (dose escalation) part of the study is designed to determine the safety,
tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RDE) of
BR101801 in patients with relapsed/refractory advanced hematologic malignancies except acute
leukemia and multiple myeloma.
The Phase Ib (dose expansion) part of the study is designed to assess tumor response and
safety in specific advanced relapsed/refractory hematologic malignances at a dose of BR101801
identified in Phase Ia.